Anzeige
Mehr »
Login
Sonntag, 26.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZK | ISIN: CA09237D1078 | Ticker-Symbol: QD6
München
24.01.25
08:01 Uhr
0,005 Euro
0,000
0,00 %
1-Jahres-Chart
BLACKHAWK GROWTH CORP Chart 1 Jahr
5-Tage-Chart
BLACKHAWK GROWTH CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0010,01425.01.
ACCESS Newswire
928 Leser
Artikel bewerten:
(2)

Blackhawk Growth Corp.: Blackhawk Growth Corp Advances Human Clinical Trials in Asthmatic AI Technology

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / April 17, 2024 / Blackhawk Growth Corp. (CSE:BLR)(Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to provide an update on Hardenbrook portfolio company - Asthmatic AI.

We are pleased to report that Asthmatic AI, a Hardenbrook and Life AI Corp asset (https://www.lifeaicorp.com) has completed 50 participants in human clinical trials and is now working on the next 250 participants as it develops its Asthma attack prediction technology for use in the clinical management of Asthma.

Uniquely, Asthmatic AI uses wearable devices and a mobile application over smartphone to collect data, assess the risk of an asthma attack occurring and then intervene before it occurs. The AI models cross reference an individual's biophysical information such as heart rate, respiratory rate, heart rate variability, blood pressure, cough and wheeze rates with public health data, pollen and location data to interpret an individual's risk of an asthma attack. With over 1000 asthma deaths reported daily according to the World Health Organization and the burden on social, employment, education and family, Asthmatic AI proposes a novel solution for the management of this serious health condition.

Hardenbrook Group works with world class research-intensive organisations to identify valuable intellectual property to invest and commercialize. This provides Blackhawk with the ability to incubate and either M&A or spin out these new innovative companies as a new listing on stock exchanges globally.

Hardenbrook has merged its portfolio of Health tech AI focused companies including Asthmatic AI, Mood AI and Autism AI with a significant pipeline of health-tech AI related projects for launch in the near horizon. Life AI Corp will be the holding company for all health tech AI companies and is also preparing to be spun out and publicly listed.

Blackhawk CEO Justin Hanka (left) and Chairman Anoosh Manzoori (right). The Board's focus is on scalable technology opportunities particularly in AI, health and enviro-tech.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies.

To receive our latest updates, please register here:

For more information on Hardenbrook: https://www.hardenbrook.group.

For more information about Life AI Corp: https://www.lifeaicorp.com

Contact

Justin Hanka. Chief Executive Officer
justin@hardenbrook.group
61433140886

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Blackhawk Growth Corp.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.